Your browser doesn't support javascript.
loading
Non-invasive risk scores for prediction of type 2 diabetes (EPIC-InterAct): a validation of existing models.
Kengne, Andre Pascal; Beulens, Joline W J; Peelen, Linda M; Moons, Karel G M; van der Schouw, Yvonne T; Schulze, Matthias B; Spijkerman, Annemieke M W; Griffin, Simon J; Grobbee, Diederick E; Palla, Luigi; Tormo, Maria-Jose; Arriola, Larraitz; Barengo, Noël C; Barricarte, Aurelio; Boeing, Heiner; Bonet, Catalina; Clavel-Chapelon, Françoise; Dartois, Laureen; Fagherazzi, Guy; Franks, Paul W; Huerta, José María; Kaaks, Rudolf; Key, Timothy J; Khaw, Kay Tee; Li, Kuanrong; Mühlenbruch, Kristin; Nilsson, Peter M; Overvad, Kim; Overvad, Thure F; Palli, Domenico; Panico, Salvatore; Quirós, J Ramón; Rolandsson, Olov; Roswall, Nina; Sacerdote, Carlotta; Sánchez, María-José; Slimani, Nadia; Tagliabue, Giovanna; Tjønneland, Anne; Tumino, Rosario; van der A, Daphne L; Forouhi, Nita G; Sharp, Stephen J; Langenberg, Claudia; Riboli, Elio; Wareham, Nicholas J.
Afiliação
  • Kengne AP; University Medical Center Utrecht, Utrecht, Netherlands; University of Cape Town and South African Medical Research Council, Cape Town, South Africa; The George Institute for Global Health, Sydney, NSW, Australia.
  • Beulens JW; University Medical Center Utrecht, Utrecht, Netherlands. Electronic address: j.beulens@umcutrecht.nl.
  • Peelen LM; University Medical Center Utrecht, Utrecht, Netherlands.
  • Moons KG; University Medical Center Utrecht, Utrecht, Netherlands.
  • van der Schouw YT; University Medical Center Utrecht, Utrecht, Netherlands.
  • Schulze MB; German Institute of Nutrition, Potsdam-Rehbruecke, Germany.
  • Spijkerman AM; National Institute for Public Health and the Environment, Bilthoven, Netherlands.
  • Griffin SJ; Medical Research Council Epidemiology Unit, Cambridge, UK.
  • Grobbee DE; University Medical Center Utrecht, Utrecht, Netherlands.
  • Palla L; Medical Research Council Epidemiology Unit, Cambridge, UK.
  • Tormo MJ; Murcia Regional Health Council, Murcia, Spain.
  • Arriola L; Public Health Division of Gipuzkoa, San Sebastian, Spain.
  • Barengo NC; Hjelt Institute, University of Helsinki, Helsinki, Finland.
  • Barricarte A; Navarre Public Health Institute, Pamplona, Spain.
  • Boeing H; German Institute of Nutrition, Potsdam-Rehbruecke, Germany.
  • Bonet C; Catalan Institute of Oncology, Barcelona, Spain.
  • Clavel-Chapelon F; Inserm, Centre for Research in Epidemiology and Population Health, U1018, Villejuif, France.
  • Dartois L; Inserm, Centre for Research in Epidemiology and Population Health, U1018, Villejuif, France.
  • Fagherazzi G; Inserm, Centre for Research in Epidemiology and Population Health, U1018, Villejuif, France.
  • Franks PW; Lund University, Malmö, Sweden.
  • Huerta JM; Murcia Regional Health Council, Murcia, Spain.
  • Kaaks R; German Cancer Research Centre, Heidelberg, Germany.
  • Key TJ; University of Oxford, Oxford, UK.
  • Khaw KT; University of Cambridge, Cambridge, UK.
  • Li K; German Cancer Research Centre, Heidelberg, Germany.
  • Mühlenbruch K; German Institute of Nutrition, Potsdam-Rehbruecke, Germany.
  • Nilsson PM; Lund University, Malmö, Sweden.
  • Overvad K; Department of Public Health, Aarhus University, Aarhus, Denmark.
  • Overvad TF; Aalborg University Hospital, Aalborg, Denmark.
  • Palli D; Cancer Research and Prevention Institute, Florence, Italy.
  • Panico S; Federico II University, Naples, Italy.
  • Quirós JR; Public Health Directorate, Asturias, Spain.
  • Rolandsson O; Umeå University, Umeå, Sweden.
  • Roswall N; Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.
  • Sacerdote C; Center for Cancer Prevention, Turin, Italy.
  • Sánchez MJ; Andalusian School of Public Health, Granada, Spain.
  • Slimani N; International Agency for Research on Cancer, Lyon, France.
  • Tagliabue G; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
  • Tjønneland A; Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark.
  • Tumino R; Cancer Registry and Histopathology Unit, Azienda Sanitaria Provinciale 7, Ragusa, Italy.
  • van der A DL; National Institute for Public Health and the Environment, Bilthoven, Netherlands.
  • Forouhi NG; Medical Research Council Epidemiology Unit, Cambridge, UK.
  • Sharp SJ; Medical Research Council Epidemiology Unit, Cambridge, UK.
  • Langenberg C; Medical Research Council Epidemiology Unit, Cambridge, UK.
  • Riboli E; Imperial College London, London, UK.
  • Wareham NJ; Medical Research Council Epidemiology Unit, Cambridge, UK.
Lancet Diabetes Endocrinol ; 2(1): 19-29, 2014 Jan.
Article em En | MEDLINE | ID: mdl-24622666
ABSTRACT

BACKGROUND:

The comparative performance of existing models for prediction of type 2 diabetes across populations has not been investigated. We validated existing non-laboratory-based models and assessed variability in predictive performance in European populations.

METHODS:

We selected non-invasive prediction models for incident diabetes developed in populations of European ancestry and validated them using data from the EPIC-InterAct case-cohort sample (27,779 individuals from eight European countries, of whom 12,403 had incident diabetes). We assessed model discrimination and calibration for the first 10 years of follow-up. The models were first adjusted to the country-specific diabetes incidence. We did the main analyses for each country and for subgroups defined by sex, age (<60 years vs ≥60 years), BMI (<25 kg/m(2)vs ≥25 kg/m(2)), and waist circumference (men <102 cm vs ≥102 cm; women <88 cm vs ≥88 cm).

FINDINGS:

We validated 12 prediction models. Discrimination was acceptable to good C statistics ranged from 0·76 (95% CI 0·72-0·80) to 0·81 (0·77-0·84) overall, from 0·73 (0·70-0·76) to 0·79 (0·74-0·83) in men, and from 0·78 (0·74-0·82) to 0·81 (0·80-0·82) in women. We noted significant heterogeneity in discrimination (pheterogeneity<0·0001) in all but one model. Calibration was good for most models, and consistent across countries (pheterogeneity>0·05) except for three models. However, two models overestimated risk, DPoRT by 34% (95% CI 29-39%) and Cambridge by 40% (28-52%). Discrimination was always better in individuals younger than 60 years or with a low waist circumference than in those aged at least 60 years or with a large waist circumference. Patterns were inconsistent for BMI. All models overestimated risks for individuals with a BMI of <25 kg/m(2). Calibration patterns were inconsistent for age and waist-circumference subgroups.

INTERPRETATION:

Existing diabetes prediction models can be used to identify individuals at high risk of type 2 diabetes in the general population. However, the performance of each model varies with country, age, sex, and adiposity.

FUNDING:

The European Union.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Modelos Biológicos Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Modelos Biológicos Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Ano de publicação: 2014 Tipo de documento: Article